Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Precigen Inc (PGEN)

Precigen Inc (PGEN)
1.5100 x 100 1.5600 x 38
Post-market by (Cboe BZX)
1.5300 +0.1600 (+11.68%) 04/22/25 [NASDAQ]
1.5100 x 100 1.5600 x 38
Post-market 1.5599 +0.0299 (+1.95%) 19:55 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.3900
Day High
1.5500
Open 1.3900
Previous Close 1.3700 1.3700
Volume 1,981,200 1,981,200
Avg Vol 1,459,465 1,459,465
Stochastic %K 74.70% 74.70%
Weighted Alpha -21.38 -21.38
5-Day Change +0.1300 (+9.29%) +0.1300 (+9.29%)
52-Week Range 0.6513 - 2.1700 0.6513 - 2.1700
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 402,839
  • Shares Outstanding, K 294,043
  • Annual Sales, $ 3,930 K
  • Annual Income, $ -126,240 K
  • EBIT $ -128 M
  • EBITDA $ -117 M
  • 60-Month Beta 1.70
  • Price/Sales 104.13
  • Price/Cash Flow N/A
  • Price/Book 10.57

Options Overview Details

View History
  • Implied Volatility 223.81% ( -100.23%)
  • Historical Volatility 102.00%
  • IV Percentile 79%
  • IV Rank 33.82%
  • IV High 539.19% on 10/09/24
  • IV Low 62.61% on 05/21/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 260
  • Volume Avg (30-Day) 834
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 19,829
  • Open Int (30-Day) 45,162

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.08
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1100 +37.84%
on 04/07/25
Period Open: 1.8100
1.8700 -18.18%
on 03/24/25
-0.2800 (-15.47%)
since 03/21/25
3-Month
1.1100 +37.84%
on 04/07/25
Period Open: 1.1300
2.1700 -29.49%
on 02/18/25
+0.4000 (+35.40%)
since 01/22/25
52-Week
0.6513 +134.91%
on 12/16/24
Period Open: 1.3800
2.1700 -29.49%
on 02/18/25
+0.1500 (+10.87%)
since 04/22/24

Most Recent Stories

More News
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

Shares of Precigen PGEN have soared nearly 43% in the past week after the company provided an encouraging regulatory update for its lead pipeline program.Last week, Precigen announced that it has completed...

CTMX : 0.7361 (-1.84%)
PGEN : 1.5300 (+11.68%)
CSTL : 21.98 (+3.97%)
INO : 1.8500 (+3.93%)
Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail Sentiment Surges Amid Stock Rally

Recurrent respiratory papillomatosis is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx.

IWC : 106.24 (+3.55%)
PGEN : 1.5300 (+11.68%)
IBB : 120.43 (+2.72%)
Precigen to Participate in Upcoming Leading Investor and Industry Conferences

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

PGEN : 1.5300 (+11.68%)
Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF, PGEN of pending class action settlements

/PRNewswire/ -- Levi & Korsinsky informs shareholders of BMRN, MAXR, SYF, PGEN that a settlement has been reached in a pending class action lawsuit against...

SYF : 48.56 (+2.82%)
PGEN : 1.5300 (+11.68%)
BMRN : 61.50 (+4.86%)
MAXR : 52.99 (+0.02%)
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025

– The FDA confirmed that the ongoing Phase 1/2 single arm study of PRGN-2012 in RRP will serve as the pivotal study to support accelerated approval and no...

PGEN : 1.5300 (+11.68%)
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

– FDA confirmed that the ongoing Phase 1/2 single arm study will serve as pivotal and no additional randomized, placebo-controlled trial will be required to...

PGEN : 1.5300 (+11.68%)
Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

PGEN : 1.5300 (+11.68%)
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerseâ„¢ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

PGEN : 1.5300 (+11.68%)
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – June 8, 2023 – USA News Group  â€“  By utilizing newly developed novel mechanisms, biotech researchers and scientists are...

ONCY : 0.6000 (+4.35%)
PGEN : 1.5300 (+11.68%)
GILD : 105.51 (+1.13%)
ONC.TO : 0.84 (+6.33%)
ITOS : 7.45 (+12.54%)
GSK : 36.63 (+0.49%)
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

/PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against...

ONCY : 0.6000 (+4.35%)
PGEN : 1.5300 (+11.68%)
GILD : 105.51 (+1.13%)
ONC.TO : 0.84 (+6.33%)
ITOS : 7.45 (+12.54%)
GSK : 36.63 (+0.49%)

Business Summary

Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional...

See More

Key Turning Points

3rd Resistance Point 1.7500
2nd Resistance Point 1.6500
1st Resistance Point 1.5900
Last Price 1.5300
1st Support Level 1.4300
2nd Support Level 1.3300
3rd Support Level 1.2700

See More

52-Week High 2.1700
Fibonacci 61.8% 1.5899
Last Price 1.5300
Fibonacci 50% 1.4107
Fibonacci 38.2% 1.2314
52-Week Low 0.6513

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro